CFE Urges Congress to Reject More Drug Price Controls

The Center for a Free Economy (CFE) recently urged the U.S. Senate Finance Committee to reject proposals that would expand federal drug price controls as lawmakers consider policies aimed at lowering prescription drug costs. In comments submitted to the committee, CFE warned against accelerating Medicare price-setting, importing foreign government price controls, and extending federal price regulation into the private insurance market.

CFE instead recommended reforms designed to strengthen competition and lower costs without undermining pharmaceutical innovation. These include greater oversight of pharmacy benefit managers, increased competition in health insurance, and passage of the bipartisan Use Sovereignty to Reduce Rx (USTRx) Act to confront foreign price controls that shift a disproportionate share of global drug development costs onto American patients.

Read CFE’s full comments below:

USTR Request for Comment.pdf

Download PDF • 423KB